Liporion

Atorvastatin, the active ingredient in Liporion, is a HMG‑CoA reductase inhibitor presented as an oral tablet for oral use. It treats hypercholesterolemia and helps reduce cardiovascular risk in adult patients with elevated lipid levels. GNH USA supplies Liporion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Atorvastatin is used to manage disorders of lipid metabolism and to lower cardiovascular risk. - Hypercholesterolemia: reduces low‑density lipoprotein (LDL) cholesterol and total cholesterol levels. - Familial hypercholesterolemia: lowers LDL cholesterol in genetically predisposed individuals. - Prevention of cardiovascular events: decreases the incidence of myocardial infarction, stroke and related events in patients with established risk factors.

Adverse reactions may occur with any medication and should be monitored.

Common Side Effects: - Muscle pain or weakness: mild to moderate myalgia without laboratory abnormalities. - Headache: transient and usually resolves without intervention. - Nausea: occasional gastrointestinal upset. - Abdominal discomfort: mild pain or cramping. - Constipation: infrequent change in bowel habits. - Diarrhea: loose stools that are typically self‑limiting.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with elevated creatine kinase. - Hepatotoxicity: significant increase in liver transaminases. - Severe allergic reaction: rash, angioedema or anaphylaxis. - Myopathy: muscle weakness with laboratory evidence of muscle injury.

Before initiating therapy, clinicians should assess patient‑specific factors and monitor for safety signals. - Liver function monitoring: obtain baseline and periodic hepatic enzyme tests. - Renal function assessment: adjust use in patients with severe renal impairment. - Avoid in active liver disease: contraindicated in patients with unexplained persistent elevations of hepatic enzymes. - Caution with CYP3A4 inhibitors: dose may need adjustment when co‑administered. - Pregnancy and lactation: safety not established; use only if potential benefit justifies risk. - Store below 25°C: keep in the original pack, protect from moisture.

Atorvastatin may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): markedly increase atorvastatin exposure. - Gemfibrozil: raises risk of myopathy and rhabdomyolysis. - Niacin (high dose): potentiates muscle toxicity. - Cyclosporine: elevates plasma concentrations, increasing adverse‑event risk.

Moderate Interactions (Monitor Closely): - Antacids (e.g., aluminum hydroxide): may modestly affect absorption. - Warfarin: potential alteration of anticoagulant effect; monitor INR. - Digoxin: possible increase in serum levels; observe for toxicity.